Sernova Biotherapeutics Inc

As of July 31, 2026, Sernova Biotherapeutics Inc carries a market capitalization of 25.83M, placing it among publicly traded companies globally. Its enterprise value stands at 34.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sernova Biotherapeutics Inc's next confirmed earnings release is scheduled for December 18, 2026.

As of July 31, 2026, Sernova Biotherapeutics Inc has 377.64M shares outstanding.

These figures are as of July 31, 2026.

As of July 31, 2026, Sernova Biotherapeutics Inc maintains a current ratio of 0.03, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -21.98, indicating conservative leverage, while an interest coverage ratio of -6.33 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended July 31, 2026. Return on assets (ROA) is negative at -1,601.72, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 8.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended July 31, 2026, Sernova Biotherapeutics Inc recorded an income tax benefit of -106,394.56 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -6.47M and -6.37M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Sernova Biotherapeutics Inc's stock has declined approximately 26.37% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.09.

Over the twelve months ended July 31, 2026, Sernova Biotherapeutics Inc generated - - in revenue and converted that into -6.37M in net income, yielding earnings per share of -0.02. EBITDA reached -5.47M, while operating income came in at -5.52M.

As of July 31, 2026, Sernova Biotherapeutics Inc holds 39,181.45 in cash and equivalents against 1.60M in total debt, resulting in a net debt position of 1.56M. Total book value stands at -14.71M, with working capital of -7.23M providing operational flexibility.

Sernova Biotherapeutics Inc produced -2.73M in operating cash flow over the twelve months ended July 31, 2026.

These figures cover the twelve months ended July 31, 2026. Free cash flow yield is negative at -11.43: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.48, meaning Sernova Biotherapeutics Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of July 31, 2026, Sernova Biotherapeutics Inc has an Altman Z-Score of -766.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.